REDWOOD CITY, Calif. -- (BUSINESS WIRE) -- Proteus Digital HealthTM, a leading digital medicines company, today announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals.
"These three professionals bring decades of strategic, commercial and financial experience to Proteus, and have a deep understanding of what is required to bring important new products to market," said Andrew Thompson, Chief Executive Officer of Proteus Digital HealthTM. "With their support, we will deliver empowering digital health products to individuals and their families."
Charles Songhurst has been appointed to the Proteus Digital Health Board of Directors, bringing significant investment and technology expertise to the company. Songhurst is Founding Partner at Katana Capital, an equity hedge fund. Previously, Songhurst ran Corporate Strategy for Microsoft and focused on partnering and M&A.
“The digital revolution is transforming markets and industries across the world,” said Songhurst. “We are seeing Silicon Valley style software and hardware innovation coming to healthcare which will increase the pace of innovation.”
Dr. Markus Christen joins Proteus as Senior Vice President and Head of Global Development, driving creation of the company’s digital medicines portfolio. Dr. Christen served as the Global Head of Strategy, Business Development and M&A for Molecular Diagnostics and eHealth at Novartis Pharma AG where he led an extensive project management portfolio in autoimmune diseases and transplantation. Dr. Christen holds a Ph.D. in Chemistry from Warwick University.
“Healthcare is changing rapidly,” said Christen. “The need to demonstrate real patient outcomes from digital medicines is a significant global opportunity. I look forward to contributing to the great progress that Proteus has already made.”
Tony Levitan joins as Senior Vice President of People, and is focused on ensuring that the human aspects of the company continue to be as impressive as the intellectual property and new products. Levitan previously founded three companies, including Egreetings Network (IPO), an early Internet innovator that created the widespread digital greetings market.
“Preeminence in digital medicine is a compelling and attractive mission for both our current and in-coming wave of Proteans,” said Levitan. “The irresistible challenge is how to establish substantial market advantage through the People group's focus on integrating talent across semiconductors, pharmaceuticals, medical devices, big data, software and mobile. No other company combines what we do at Proteus."
About Proteus Digital Health
Proteus Digital Health is pioneering a new category of products and services based on ingestion sensing. Its core technology—the digital health feedback system—provides an unprecedented view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models. Proteus received a CE mark in August 2010 for its technology platform and U.S. FDA market clearance in July 2012 for its ingestible sensor. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, ON Semiconductor and other investors. For more information, please visit www.proteus.com.